Neutralizing antibodies to biological therapies: A "touch of gray" vs a "black and white" story.
Freedman
Mark S
MS
Pachner
Andrew R
AR
D019138:Antibodies, Blocking / Q000032:analysis / Q000097:blood / Q000276:immunology*; D000911:Antibodies, Monoclonal / Q000276:immunology* / Q000494:pharmacology / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000918:Antibody Specificity / Q000276:immunology; D001666:Binding Sites, Antibody / Q000276:immunology; D006801:Humans; D007167:Immunotherapy / Q000379:methods* / Q000592:standards; D009103:Multiple Sclerosis / Q000188:drug therapy / Q000276:immunology*; D000069442:Natalizumab
D019138:Antibodies, Blocking; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069442:Natalizumab